Short answer
Sanara MedTech Inc. (SMTI) filed an 8-K current report with the SEC on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item EX-99.1 (Exhibit EX-99.1). Filing contains only signature information dated August 11, 2026.
Sanara MedTech Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 2.02 · Results of Operations and Financial Condition
- Filing contains only signature information dated August 11, 2026
- No earnings figures or operating results included in the provided Item 2.02 text
Item EX-99.1 · Exhibit EX-99.1
- Q2 revenue rose 9% to $28.1M, led by soft-tissue products up 11%; bone-fusion sales declined 8%
- Gross margin improved to 93% from 92%, but operating income fell to $1.8M as expenses increased 14% to $24.4M
- Q2 continuing-operations loss reached $0.4M, or $0.05 per diluted share, versus $0.5M income previously
- Six-month Adjusted EBITDA increased to $9.3M from $7.4M, while operating cash flow turned negative at $0.4M
- Proposed MiMedx acquisition creates transaction-related upside but remains subject to shareholder, regulatory, and closing conditions
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Sanara MedTech Inc. 8-K filings
Get the next SMTI 8-K as it lands
Follow SMTI for push alerts, or ask the research agent what this filing means.